Valuation
- Market cap
- 2,068,000
- Revenue TTM
- $1,040,000
- Net income TTM
- $-48,170,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -4,631.73%
- Debt to equity
- -0.30
Trading
- Volume
- 7,400
- Avg volume
- 1,062
- Day's range
- $0.00 – $0.40
- Shares out
- 5,169,000
- Stochastic %K
- 69%
- Beta
- 2.86
- Analysts
- Strong Buy
- Price target
- $6.00
Company profile
Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of...
Show more
Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. It also provides hospital services and cell process development services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 480 659 6404
- Website
- https://orgenesis.com
- Address
- 20271 Goldenrod Lane, Germantown, United States
Latest news
No headlines yet.
